Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
Zahra Safarzadeh/LinkedIn
Sep 9, 2026, 16:07

Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance

Zahra Safarzadeh, Clinical Laboratory Scientist at Shahid Dastgheib Hospital, Shiraz University of Medical Sciences, shared a post on LinkedIn:

“A novel F8 variant is found. What happens next?

Finding a previously unreported variant in the F8 gene can be exciting.

But ‘novel’ does not automatically mean ‘pathogenic.’

A new F8 variant should trigger a structured investigation.

1. Confirm the variant

Is the variant technically reliable and correctly described?

2. Check population databases

Is it absent or extremely rare in relevant population databases?

3. Assess the variant type

Does it affect a critical splice site, introduce a premature stop codon, alter an important amino acid, or involve a deletion or duplication?

4. Review existing evidence

What do ClinVar, published literature, and other curated resources tell us?

5. Correlate with the phenotype

Does the patient’s FVIII activity and bleeding phenotype support the molecular finding?

6. Investigate the family

Segregation analysis can provide important evidence.

Is the variant present in affected family members?

Is it absent in unaffected relatives?

7. Consider de novo status when appropriate

If a variant appears to be de novo, parental testing and confirmation of biological relationships are important before using this as evidence for interpretation.

Then comes the critical step:

ACMG/AMP variant interpretation.

The goal is not simply to label a variant.

The goal is to integrate multiple lines of evidence and determine what the variant most likely means clinically.

A novel variant may ultimately be classified as:

Pathogenic | Likely Pathogenic | VUS | Likely Benign | Benign

And sometimes, the most scientifically responsible answer is:

‘We need more evidence.’

That is not a failure of molecular diagnosis.

It is appropriate scientific interpretation.

A novel variant is a finding.

Its clinical meaning is a conclusion that must be earned by evidence.”

Zahra Safarzadeh

Stay updated with Hemostasis Today.

bleeding bleeding disorders Blood F8 haemophilia Health Hematology Hemophilia Hemophilia A Hemophilia B Hemostasis Hemostasis News Hemostasis Today Medical Genetics Medicine Zahra Safarzadeh
NewsFeed